{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:03:03Z","timestamp":1788498183222,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Anaplastic lymphoma kinase (\n                    <jats:italic>ALK<\/jats:italic>\n                    ) rearrangements are exceedingly rare in gastric cancer, and uncommon fusion types add to the difficulties of proper, precise treatment strategies. Although detected in non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors (IMTs), and Spitz tumors, the\n                    <jats:italic>DCTN1\u2013ALK<\/jats:italic>\n                    fusion has not previously been reported in gastric cancer. This report describes the first case of gastric adenocarcinoma harboring a\n                    <jats:italic>DCTN1\u2013ALK<\/jats:italic>\n                    fusion that was successfully treated with the ALK-targeted agent alectinib after first- and second-line chemotherapy-based regimens had failed. Progression-free survival on alectinib was 11.5 months until KRAS amplification emerged on serial circulating tumor DNA analysis, leading to rapid systemic relapse. The other documented cases with\n                    <jats:italic>DCTN1\u2013ALK<\/jats:italic>\n                    fusion treated with the first or second generation of ALK inhibitors indicated this rare fusion as an actionable driver gene mutation. This successful personalized anti-tumor strategy highlights the clinical utility of comprehensive genomic profiling and liquid biopsy in detecting and monitoring actionable\n                    <jats:italic>ALK<\/jats:italic>\n                    fusions in solid tumors.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1686666","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:23:05Z","timestamp":1761805385000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Response to anaplastic lymphoma kinase inhibitor in gastric cancer harboring DCTN1\u2013ALK fusion: a case report and review"],"prefix":"10.3389","volume":"16","author":[{"given":"Huadi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangkun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4376-8","article-title":"The clinicopathologic features and prognostic impact of ALK positivity in patients with resected gastric cancer","volume":"22","author":"Chon","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Deng","year":"2012","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2203","article-title":"Molecular classification of gastric cancer: A new paradigm","volume":"17","author":"Shah","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0479-T","article-title":"ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers","volume":"12","author":"Aisner","year":"2014","journal-title":"Mol Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0058","article-title":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","volume":"15","author":"Singhi","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1758834014567117","article-title":"Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract","volume":"7","author":"Alese","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2200015","DOI":"10.1200\/PO.22.00015","article-title":"ALK inhibitors in patients with ALK fusion-positive GI cancers: an international data set and a molecular case series","volume":"6","author":"Ambrosini","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"12510","DOI":"10.1038\/s41598-017-12679-8","article-title":"Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches","volume":"7","author":"Vendrell","year":"2017","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14291","article-title":"Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion","volume":"13","author":"Yin","year":"2022","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14345","article-title":"Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALKandALK-CLIP4 rearrangements","volume":"13","author":"Gao","year":"2022","journal-title":"Thorac Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-015-0160-2","article-title":"STUMP un\u201dstumped\u201d: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion","volume":"8","author":"Subbiah","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/2152-7806.112614","article-title":"Inflammatory myofibroblastic tumors of the central nervous system that express anaplastic lymphoma kinase have a high recurrence rate","volume":"4","author":"Denis","year":"2013","journal-title":"Surg Neurol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Andr\u00e9","year":"2017","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645370","article-title":"Case report: RAB10-ALK: A novel ALK fusion in a patient with gastric cancer","volume":"11","author":"Wen","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-0406-0","article-title":"The dynactin subunit DCTN1 controls osteoclastogenesis via the Cdc42\/PAK2 pathway","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.191","article-title":"Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases","volume":"31","author":"Dickson","year":"2018","journal-title":"Modern Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0194","article-title":"An oncogenic ALK fusion and an RRAS mutation in KRAS mutation-negative pancreatic ductal adenocarcinoma","volume":"22","author":"Shimada","year":"2017","journal-title":"Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0439","article-title":"Carcinoma of unknown primary with EML4-ALK fusion response to ALK inhibitors","volume":"24","author":"Zhao","year":"2019","journal-title":"Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686666\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:23:06Z","timestamp":1761805386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1686666\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2025.1686666"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1686666","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"1686666"}}